A Silicon Valley AI shop has been OK’d by the FDA to market software that automatically flags suspected pulmonary embolisms (PEs) and immediately notifies physicians.
San Mateo-based RapidAI announced the FDA go-ahead May 24, saying its Rapid PE Triage & Notification product speeds triaging of patients and alerting of care teams, in the process cutting time to treatment.
The newly cleared offering is designed to work with CT pulmonary angiogram (CTPA) images, optimally in conjunction with another RapidAI product, Rapid Workflow for PE.
The announcement quotes interventional cardiologist Jimmy Kerrigan, MD, of Ascension St. Thomas Heart in Tennessee.
Kerrigan suggests the new FDA clearance shows how “artificial intelligence will transform the way we triage and manage pulmonary embolism, a historically complicated process involving a diverse care team … I’m optimistic about its potential to optimize our care for patients and to hopefully improve patient outcomes.”
More Coverage of Recently Cleared Imaging Technology:
FDA greenlights expansion of CT-guided, robotically supported IR system
FDA warns providers about potential misuse of imaging-based software for stroke triage
FDA greenlights portable, wearable 3D breast POCUS
FDA clears Aidoc artificial intelligence solution for flagging suspected brain aneurysm cases
FDA clears GE Healthcare X-ray artificial intelligence aid for endotracheal tube placement
Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.